Stimus (darbepoetin alfa biosimilar)
/ Nanogen Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 31, 2025
Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis
(clinicaltrials.gov)
- P1 | N=43 | Completed | Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company | Active, not recruiting ➔ Completed
Trial completion • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease
March 27, 2025
A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)
(clinicaltrials.gov)
- P3 | N=214 | Completed | Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company | Active, not recruiting ➔ Completed
Trial completion • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease
1 to 2
Of
2
Go to page
1